C4 Therapeutics (CCCC) Shares Outstanding (Weighted Average) (2019 - 2026)

C4 Therapeutics has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $126.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 77.99% year-over-year to $126.1 million; the trailing twelve-month figure through Mar 2026 stood at $126.1 million (up 77.99% YoY), and the FY2025 full-year result was $28.7 million, down 58.61% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $126.1 million, up from $28.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $126.1 million in Q1 2026, with the low at $28.7 million in Q4 2025.
• Average Shares Outstanding (Weighted Average) over 5 years is $61.0 million, with a median of $49.6 million recorded in 2023.
• Year-over-year, Shares Outstanding (Weighted Average) sank 58.61% in 2025 and soared 77.99% in 2026.
• Tracing CCCC's Shares Outstanding (Weighted Average) over 5 years: stood at $48.9 million in 2022, then rose by 1.59% to $49.6 million in 2023, then soared by 39.75% to $69.4 million in 2024, then slumped by 58.61% to $28.7 million in 2025, then soared by 339.08% to $126.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $126.1 million (Q1 2026), $28.7 million (Q4 2025), and $72.6 million (Q3 2025), per Business Quant data.

Peer Comparison